Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optison Safety Study on Pulmonary Hemodynamics
NCT00878878Phase 4Completed
- Sponsor
- GE HealthCare
- Start
- Mar 2009
- Primary completion
- Jul 2010
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of perflutren lipid microspheres in pulmonary hypertension (PH) (2 arms), sponsored by GE HealthCare. Primary endpoints: Pulmonary Artery Systolic Pressure at 10 minutes and Pulmonary Vascular Resistance at 10 minutes. Started Mar 2009; status: completed.
02
Drugs
perflutren lipid microspheres
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT00878878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00878878.